Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference
Open Access
- 28 April 2009
- Vol. 115 (S10), 2247-2251
- https://doi.org/10.1002/cncr.24229
Abstract
The Third Cambridge Conference on Innovations and Challenges in Renal Cancer, a symposium held in Cambridge, Massachusetts, June 27‐28, 2008, and chaired by Michael B. Atkins, was convened to discuss the current state of knowledge in the field, critique new data, stimulate communication among those involved in basic and clinical research, and offer recommendations for further study. Four main topics were discussed: genetics and molecular biology of renal cell cancer, staging and prognosis, systemic therapy, and correlative science and biomarkers in stage IV disease. The conference format combined brief presentations with extended periods of discussion. The conclusions and recommendations are summarized in this paper and presented in more detail in the individual papers that follow. Cancer 2009;115(10 suppl):2247‐51. © 2009 American Cancer Society.Keywords
Funding Information
- Genentech, Novartis Pharmaceuticals, Pfizer, Inc., and Wyeth Pharmaceuticals
- National Institutes of Health, National Cancer Institute, Center for Cancer Research
- Bayer and Novartis
- Bayer and Pfizer
- Amgen, GlaxoSmithKline, Pfizer, and Wyeth
This publication has 14 references indexed in Scilit:
- Renal Cell Carcinoma: Dynamic Contrast-enhanced MR Imaging for Differentiation of Tumor Subtypes—Correlation with Pathologic FindingsRadiology, 2009
- Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screenProceedings of the National Academy of Sciences, 2008
- Magnetic Resonance Imaging–Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell CarcinomaClinical Cancer Research, 2008
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted TherapeuticsClinical Cancer Research, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sunitinib in Patients With Metastatic Renal Cell CarcinomaJAMA, 2006
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma.2001
- Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2Annals of Surgery, 1998